Etid klinik pou Sipwa nan Massachusetts
24 etid pou Sipwa ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Brigham and Women's Hospital Diabetes Program, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Boston Children's Hospital, Boston
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Lucida Clinical Trials, New Bedford
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Lucida Clinical Trials, New Bedford
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Care Access - Quincy, Quincy
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Brigham and Womens Hospital, Boston
- Btc of New Bedford, New Bedford
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Brigham and Women's Hospital Diabetes Program, Boston
- MedVadis Research Corporation, Waltham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Knownwell, Needham
- Lucida Clinical Trials, New Bedford
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Skylight Health Research - Burlington, Burlington
- Care Access - Quincy, Quincy
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Lucida Clinical Trials, New Bedford
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, North Dartmouth
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Boston Medical Center, Boston
- Knownwell, Needham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression
- Massachusetts General Hospital, Boston
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT07699445A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Methuen
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Knownwell, Needham
- Lucida Clinical Trials, New Bedford
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Metro Boston Clinical Partners, Brighton
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
- Exponent Boston, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07776678Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Methuen
- ACCOMPLISH-1 Research Site, Needham
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Family-Based Weight Wellness Treatment Through Food is Medicine and Group Medical Visits in Pediatric and Adult Primary Care
- Tufts Medical Center, Boston
- Tufts University, Boston
Ap rekrite
Laj 12 a 17 · Tout sèks · Mizajou Jul 21, 2026 · NCT07717658Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
- Cambridge Health Alliance, Sommerville
Ap rekrite
Laj 18 a 60 · Tout sèks · Mizajou Jul 16, 2026 · NCT06988462Time Restricted Eating (TRE) in Bipolar Disorder
- Massachusetts General Hospital, Boston
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Jun 15, 2026 · NCT07211217Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
- Massachusetts General Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 a 65 · Tout sèks · Mizajou Dec 24, 2025 · NCT05799222Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
- Brigham and Women's Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT06069622Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.